///PRP & Gluteal Tendinopathy

PRP & Gluteal Tendinopathy

The Effectiveness of Platelet-Rich Plasma Injections in Gluteal Tendinopathy: A Randomized, Double-Blind Controlled Trial Comparing a Single Platelet-Rich Plasma Injection With a Single Corticosteroid Injection.

Abstract

BACKGROUND:

Gluteus medius/minimus tendinopathy is a common cause of lateral hip pain or greater trochanteric pain syndrome.

HYPOTHESIS:

There would be no difference in the modified Harris Hip Score (mHHS) between a single platelet-rich plasma (PRP) injection compared with a corticosteroid injection in the treatment of gluteal tendinopathy.

STUDY DESIGN:

Randomized controlled trial; Level of evidence, 1.

METHODS:

There were 228 consecutive patients referred with gluteal tendinopathy who were screened to enroll 80 participants; 148 were excluded (refusal: n = 42; previous surgery or sciatica: n = 50; osteoarthritis, n = 17; full-thickness tendon tear, n = 17; other: n = 22). Participants were randomized (1:1) to receive either a blinded glucocorticoid or PRP injection intratendinously under ultrasound guidance. A pain and functional assessment was performed using the mHHS questionnaire at 0, 2, 6, and 12 weeks and the patient acceptable symptom state (PASS) and minimal clinically important difference (MCID) at 12 weeks.

RESULTS:

Participants had a mean age of 60 years, a ratio of female to male of 9:1, and mean duration of symptoms of >14 months. Pain and function measured by the mean mHHS showed no difference at 2 weeks (corticosteroid: 66.95 ± 15.14 vs PRP: 65.23 ± 11.60) or 6 weeks (corticosteroid: 69.51 ± 14.78 vs PRP: 68.79 ± 13.33). The mean mHHS was significantly improved at 12 weeks in the PRP group (74.05 ± 13.92) compared with the corticosteroid group (67.13 ± 16.04) ( P = .048). The proportion of participants who achieved an outcome score of ≥74 at 12 weeks was 17 of 37 (45.9%) in the corticosteroid group and 25 of 39 (64.1%) in the PRP group. The proportion of participants who achieved the MCID of more than 8 points at 12 weeks was 21 of 37 (56.7%) in the corticosteroid group and 32 of 39 (82%) in the PRP group ( P = .016).

CONCLUSION:

Patients with chronic gluteal tendinopathy >4 months, diagnosed with both clinical and radiological examinations, achieved greater clinical improvement at 12 weeks when treated with a single PRP injection than those treated with a single corticosteroid injection. Registration: ACTRN12613000677707 (Australian New Zealand Clinical Trials Registry).

By |2018-10-02T22:30:32+00:00February 4th, 2018|Blog|Comments Off on PRP & Gluteal Tendinopathy

FAQ:

PRP means Platelet Rich Plasma. The Plasma liquid in the blood includes red and white blood cells and platelets. Platelets form 10% of the plasma and in the concept of PRP, the platelet ratio is flipped to 90%. It is given in the form of an injection to patients looking to treat tissue damages, skin issues etc.
A non-surgical therapy in nature, PRP is used for healing in several medicine fields including sports medicines and orthopedics. PRP is nothing but the patient’s own blood which is administered in a way such that the healing components (growth factors) present in the platelets are released, thus fuelling fast recovery.
PRP is majorly useful in cases of soft tissue injuries, including ligament sprains, muscle pulls / tears, tendon tears, tendonitis and tendinosis. It has been an effective way to treat cartilage degeneration like arthritis as well.
With its methodology, PRP is developed to heal the injured region through the initiation of growth factors in your platelets. It is a cure and not just a temporary solution to limit any injury.
In most cases, the procedure can be well tolerated by patients but there may be soreness after the injection as PRP induces

CONTACT:

1340 Tully Rd #314
San Jose, CA 95122

866.704.8572

866.817.1181


New client pricing-

2 kits for $49!

prp-sidebar

Want to get in touch? Please do, we’d love to hear from you.

For general inquiries, you can fill out and submit your contact information. We also encourage you to call our offices directly at 866.704.8572 for the most current information.